CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 135 filers reported holding CYMABAY THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $3,670,548 | +35.6% | 155,400 | -14.4% | 0.00% | +50.0% |
| Q3 2023 | $2,706,165 | +55.5% | 181,500 | +14.2% | 0.00% | +100.0% |
| Q2 2023 | $1,739,955 | +9.2% | 158,900 | -13.0% | 0.00% | 0.0% |
| Q1 2023 | $1,593,144 | +221.8% | 182,700 | +67.6% | 0.00% | – |
| Q1 2021 | $495,000 | -20.9% | 109,000 | 0.0% | 0.00% | – |
| Q4 2020 | $626,000 | +257.7% | 109,000 | -7.9% | 0.00% | – |
| Q1 2020 | $175,000 | -24.6% | 118,400 | 0.0% | 0.00% | – |
| Q4 2019 | $232,000 | -60.9% | 118,400 | +2.2% | 0.00% | -100.0% |
| Q3 2019 | $593,000 | -26.6% | 115,900 | +2.7% | 0.00% | 0.0% |
| Q2 2019 | $808,000 | -45.0% | 112,900 | +2.1% | 0.00% | -50.0% |
| Q1 2019 | $1,469,000 | +88.1% | 110,600 | +11.5% | 0.00% | +100.0% |
| Q4 2018 | $781,000 | -27.1% | 99,200 | +2.6% | 0.00% | 0.0% |
| Q3 2018 | $1,071,000 | -17.5% | 96,700 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,298,000 | – | 96,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 1,641,804 | $11,887,000 | 8.85% |
| Foresite Capital Management IV, LLC | 1,787,094 | $12,939,000 | 2.92% |
| Copernicus Capital Management, LLC | 278,416 | $2,016,000 | 1.92% |
| Sio Capital Management, LLC | 1,159,236 | $8,393,000 | 1.66% |
| ACUTA CAPITAL PARTNERS, LLC | 765,000 | $5,539,000 | 1.50% |
| Avoro Capital Advisors LLC | 10,300,000 | $74,572,000 | 1.06% |
| Boxer Capital, LLC | 4,000,000 | $28,960,000 | 1.00% |
| Vivo Capital, LLC | 2,089,356 | $15,127,000 | 0.87% |
| EAM Global Investors LLC | 284,534 | $2,060,000 | 0.76% |
| Versant Venture Management, LLC | 543,753 | $3,937,000 | 0.72% |